Press Releases
March 13, 2013
Avedro Announces Preparation for Anticipated Hyperopic Lasik Xtra® US Clinical Trial
March 5, 2013
Avedro Completes $43 Million Series D Financing
Abingworth and Third Point Join Existing Investors
October 25, 2012
Avedro and EyeGate Pharma Enter Agreement for Corneal Cross-linking IP
Avedro to hold exclusive license to broad iontophoresis patent portfolio
October 11, 2012
Keraflex® Keratoconus Treatment Study Begins in US
Hersh Vision Group is the first to offer this novel keratoconus treatment
June 12, 2012
Avedro Announces CE Mark for its Newest Riboflavin Formulations
The First Complete Family of Cross-linking Products
May 2, 2012
Avedro to Present Seven Scientific Research Posters at Leading Ophthalmic Meeting
April 3, 2012
ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking
March 8, 2012
Avedro Announces FDA Submission for Corneal Cross-linking
February 28, 2012
Avedro Options Rights to Intellectual Property
Avedro Options Rights to Intellectual Property
January 30, 2012
Canadian Approval for Lasik Xtra_Press Release
January 4, 2012
Avedro Announces CE Approval for Lasik Xtra ™
Intra-operative Lasik Cross-linking Receives Important European Recognition
December 6, 2011
Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking
VibeX™ Riboflavin/KXL™ System for the Treatment of Corneal Ectasia Following Refractive Surgery
October 13, 2011
Avedro Appoints A. John Kanellopoulos, MD to its Medical Advisory Board
Dr. Kanellopoulos is globally recognized as a pioneer in refractive surgery and corneal cross-linking
September 28, 2011
Avedro Appoints C. Evan Ballantyne as Chief Financial Officer
The Company Prepares for Rapid Commercialization
September 14, 2011
Avedro Acquires Patent Portfolio for Breakthrough Transepithelial Riboflavin
Inventor Roberto Pinelli, MD will join the Avedro Medical Advisory Board
September 12, 2011
Avedro Announces FDA Orphan Drug Designation for Its Corneal Cross-linking
VibeX™ Riboflavin/KXL™ System for the Treatment of Keratoconus
July 20, 2011
Avedro and Japan’s Shinagawa LASIK Centers Announce Their Expanded Commercial Relationship
The Shinagawa LASIK Center in Tokyo has performed more Lasik surgeries than any other center in the world
July 7, 2011
Avedro Completes $25 Million Series C Financing
SCP Vitalife and Aperture Venture Partners join existing investors
May 17, 2011
Avedro Announces Completion of 1st US Phase III Corneal Cross-linking Clinical Trials
Multi-center US Phase III Studies for the Treatment of Progressive Keratoconus and Ectasia Following Refractive Surgery
Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device Avedro Becomes Sponsor of US FDA Clinical Trials of Corneal Collagen Crosslinking Avedro Initiates Keraflex® KXL Clinical Trials for Treating KeratoconusApril 20, 2010
The company prepares for immediate commercial launch throughout Europe and AsiaMarch 16, 2010
Deal opens a new and substantial business opportunity for Avedro’s Keraflex® KXLDecember 16, 2009
Initial results demonstrate significant corneal flattening, improved visual outcomes
The Vedera for performing the Keraflex procedure, and the KXL System for Accelerated Cross-linking are not available for sale in the United States.